Quick Win by the Algorithm: Stein Mart Inc. (NASDAQ: SMRT) Returns up to 28.95% in 7 Days

“We are encouraged by the sales trend we saw in February and early March driven by very strong regular-priced selling, particularly in our warm weather and resort markets where spring selling begins. These leading indicators give us confidence that comparable sales trends will dramatically improve in the first quarter as spring regular-price selling builds in other markets. With improved first quarter comparable sales, our gross profit expansion and continued expense control, we expect first-half operating income in excess of $8 million, most of which will occur in the first quarter.”

-Said

Read More

Stock Forecast: Netflix (NFLX) Stocks Leap As Subscriber Gains Beat Estimates

Stock Forecast:

[Source: Wikimedia Commons]

“At Netflix, we think you have to build a sense of responsibility where people care about the enterprise. Hard work, like long hours at the office, doesn’t matter as much to us. We care about great work”

— Netflix CEO Reed Hastings

Netflix now has 125 million members worldwide

Shortly after Netflix (NFLX) published their Q1 Earnings Report after market hours on April 16th, 2018, Netflix’s stock soared from a closing price of $307.78 to $323.75 per share after hours, increasing roughly 7% before the market open alone. Over the past year, Netflix has outperformed

Read More

Successful Stock Forecast: Capston Turbine Corporation (NASDAQ: CPST) Gained High Momentum Of 26.39% In 3 Days

Successful Stock Forecast

“A key component to Capstone’s growth strategy is to increase our quarterly aftermarket service revenue and expand aftermarket gross margins to the point that they cover 100% of our quarterly operating costs”

– Darren Jamison, President and Chief Executive Officer of Capstone

CPST office

[Image Source: Regatta Solutions]

Over the 3 days period starting from April 9, 2018, Capstone Turbine’s stock price experienced steep price rise of more than 26%. Taking into account the overall CPST stock performance of +49.35% during fiscal year ended on March 31, 2018, it is it is reasonable to

Read More

Quick Win by the Algorithm: Stage Stores, Inc. (NYSE: SSI) Returns up to 26.36% in 14 Days

“We are optimistic about 2018 and remain focused on building upon the momentum we established in our department store sales. In addition, our acquisition of Gordmans is a great opportunity for us to leverage the strength of the off-price sector, and we plan to accelerate growth in this business during the coming year. As a result, in 2018, we expect to deliver positive comparable sales, significantly improve EBIT, and generate positive free cash flow.”

-Said Mr. Glazer President, Chief Executive Officer and Director of Stage Stores Inc.

[Image Source: Wikipedia]

Stage Stores, Inc

Read More

Quick Win by the Algorithm: Bitauto Holdings Limited (NYSE: BITA) Dives Deep Under Market Surface Down To -30.73% In 1 Month

Quick Algorithm

“As we continue to make healthy progress across our business lines, we are optimistic about Bitauto’s profitability outlook for 2018. We expect to expand margins over the coming quarters as we drive cost saving synergies between Bitauto and Yixin, increased efficiencies in our media business, and economies of scale from Yixin.”

– Ms. Cynthia He, Chief Financial Officer of Bitauto

BITA logo

[Image Source: www.ticker.tv]

Over the March Bitauto stock price experienced ups and downs. During the first third of the month the stock price oscillated around $29 per share and jumped up

Read More

Quick Win by the Algorithm: Sangamo Therapeutics (NASDAQ: SGMO) Returns Up To 278.00% In 1 Year And Promises Bright Future

” This year we continue the important work of laying the foundation for Sangamo as a sustainable, fully integrated company that develops, manufacturers and commercializes novel genomic therapies on our own and, where appropriate, in collaboration with industry partners. “

-Sandy Macrae, CEO of Sangamo.

[Image source: Businesswire.com]

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a clinical stage biopharmaceutical company that focuses on the research, development, and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene

Read More

Quick Win by the Algorithm: Geron Corporation (NASDAQ: GERN) Treats Investors With Stock Up 24.71% In 3 Days

Quick Algorithm

“With the preliminary data from IMerge presented at ASH, we now have clinical data in three blood cancers, ET, MF and MDS, where imetelstat exhibits potential disease modifying activity by inhibiting the progenitor cells of the malignant clones that drive the underlying diseases”

– said John A. Scarlett, M.D., Geron’s President and Chief Executive Officer.

(Image Source: www.troutaccess.com)

Geron Corporation (NASDAQ: GERN) operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the

Read More